Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.55 +2.5%	$21.37	$13.40 ▼ $25.23	$3.68B	0.64	1.98 million shs	2.09 million shs
ALKS Alkermes	$29.20 +1.2%	$30.09	$24.40 ▼ $36.45	$4.76B	0.44	1.73 million shs	1.66 million shs
BOLT Bolt Biotherapeutics	$5.74 +1.6%	$6.18	$5.20 ▼ $15.60	$10.83M	0.89	11,867 shs	26,487 shs
DVAX Dynavax Technologies	$10.67 +2.2%	$10.06	$9.22 ▼ $14.63	$1.25B	1.03	2.15 million shs	897,503 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.55%	+4.71%	+1.38%	+51.06%	+22.07%
ALKS Alkermes	-2.83%	-1.80%	-3.29%	+6.07%	+23.45%
BOLT Bolt Biotherapeutics	-4.36%	-5.63%	-6.56%	-14.16%	-60.95%
DVAX Dynavax Technologies	-2.79%	-1.42%	+1.66%	-1.97%	-1.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.1007 of 5 stars	3.4	3.0	0.0	2.7	4.2	2.5
ALKS Alkermes	4.8354 of 5 stars	4.4	1.0	4.2	4.0	2.5	1.9
BOLT Bolt Biotherapeutics	2.5408 of 5 stars	3.2	2.0	0.0	2.7	1.7	1.3
DVAX Dynavax Technologies	4.4402 of 5 stars	3.3	2.0	4.7	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	23.61% Upside
ALKS Alkermes	2.83	Moderate Buy	$40.92	40.13% Upside
BOLT Bolt Biotherapeutics	2.33	Hold	$50.00	771.08% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	124.93% Upside

Current Analyst Ratings Breakdown

Latest DVAX, ACAD, ALKS, and BOLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.94	$0.72 per share	31.23	$4.40 per share	5.13
ALKS Alkermes	$1.56B	3.09	$2.68 per share	10.88	$9.05 per share	3.23
BOLT Bolt Biotherapeutics	$7.69M	1.43	N/A	N/A	$29.89 per share	0.19
DVAX Dynavax Technologies	$277.25M	4.62	$0.16 per share	65.93	$4.54 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.46	29.67	4.74	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ALKS Alkermes	$367.07M	$2.09	13.97	21.31	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
BOLT Bolt Biotherapeutics	-$63.12M	-$33.40	N/A	N/A	N/A	N/A	-94.51%	-59.07%	8/12/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	21.78	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)

Latest DVAX, ACAD, ALKS, and BOLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	BOLT Bolt Biotherapeutics	-$6.40	N/A	N/A	N/A	$0.82 million	N/A
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
8/5/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	N/A	N/A	N/A	$87.55 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/12/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$6.80	-$5.80	+$1.00	-$0.29	$0.77 million	$1.22 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ALKS Alkermes	N/A	3.33	2.92
BOLT Bolt Biotherapeutics	0.48	3.13	3.13
DVAX Dynavax Technologies	0.49	11.93	10.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ALKS Alkermes	95.21%
BOLT Bolt Biotherapeutics	86.70%
DVAX Dynavax Technologies	96.96%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ALKS Alkermes	4.40%
BOLT Bolt Biotherapeutics	6.10%
DVAX Dynavax Technologies	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.80 million	Not Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable

DVAX, ACAD, ALKS, and BOLT Headlines

Recent News About These Companies

Cambridge Investment Research Advisors Inc. Makes New $312,000 Investment in Dynavax Technologies Corporation (NASDAQ:DVAX)

July 13 at 3:19 AM | marketbeat.com

Dynavax Technologies Corporation (DVAX) - Yahoo Finance

July 12, 2025 | finance.yahoo.com

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

July 7, 2025 | finance.yahoo.com

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

July 6, 2025 | insidermonkey.com

DVAX - Dynavax Technologies Corp Key Metrics - Morningstar

July 5, 2025 | morningstar.comM

DVAX Dynavax Technologies Corporation - Seeking Alpha

June 28, 2025 | seekingalpha.com

93,841 Shares in Dynavax Technologies Corporation (NASDAQ:DVAX) Acquired by Advisor Resource Council

June 21, 2025 | marketbeat.com

SG Americas Securities LLC Reduces Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

June 21, 2025 | marketbeat.com

Exchange Traded Concepts LLC Cuts Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

June 18, 2025 | marketbeat.com

Chicago Capital LLC Has $69.32 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

June 17, 2025 | marketbeat.com

Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

Dynavax re-elects all board members, despite Deep Capital's push to change

June 11, 2025 | msn.com

Dynavax elects all four of its nominees after Deep Track proxy fight

June 11, 2025 | reuters.com

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

June 11, 2025 | prnewswire.com

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

June 9, 2025 | finance.yahoo.com

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...

June 9, 2025 | gurufocus.com

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...

June 9, 2025 | gurufocus.com

Deep Track Capital Pushes for Board Changes at Dynavax Technologies Corp (DVAX) | DVAX stock news

June 9, 2025 | gurufocus.com

Dynavax Technologies Corp (DVAX) Urges Stockholders to Support Director Nominees | DVAX stock news

June 9, 2025 | gurufocus.com

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

June 9, 2025 | prnewswire.com

Vaccine maker Dynavax's future hangs in balance amid activist investor showdown

June 5, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVAX, ACAD, ALKS, and BOLT Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.55 +0.54 (+2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$22.68 +0.13 (+0.59%)

As of 07:57 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Alkermes NASDAQ:ALKS

$29.20 +0.35 (+1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$29.19 -0.01 (-0.03%)

As of 07:34 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Bolt Biotherapeutics NASDAQ:BOLT

$5.74 +0.09 (+1.59%)

Closing price 03:59 PM Eastern

Extended Trading

$5.75 +0.01 (+0.17%)

As of 07:22 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Dynavax Technologies NASDAQ:DVAX

$10.67 +0.23 (+2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$10.92 +0.25 (+2.38%)

As of 07:43 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time